December 18, 2018 – Since the first case was identified in Illinois on March 3, 2018, state health departments have reported 202 additional cases of life-threatening vitamin K-antagonist dependent coagulopathy in patients who took synthetic cannabinoids. Five people died before this report in May 2018. CDC reported 94 cases in 5 states — including 2 deaths — at the time.
Free Confidential Lawsuit Evaluation: If you or a loved one has been injured by the side effects of synthetic cannabinoids, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
What’s the Problem?
The same day this report was published in the CDC Health Alert Network, the following states reported cases of vitamin K-antagonist dependent coagulopathy associated with synthetic cannabinoid use:
- Illinois (164 cases)
- Maryland (20 cases)
The following states reported 6 cases or less:
More than 95 biological samples of patients were tested positive for brodifacoum, a highly lethal vitamin K antagonist anticoagulant used in commercial products to kill rodents and other pests.
Vendors sell synthetic cannabinoids under a variety of names, including K2 and Spice. The adverse effects of using the products vary and may include neurological, psychiatric signs and symptoms, and other physical effects.
Patients in this multi-state epidemic showed various symptoms of coagulopathy, such as bruising, nosebleeds, excessive menstrual bleeding, hematemesis, hemoptysis, hematuria, lateral pain, abdominal pain and gum bleeding in the mouth, CDC said.
Some patients were asymptomatic or had problems unrelated to bleeding, but had “numerical coagulopathy” that could lead to a risk of bleeding complications associated with injury and invasive or surgical procedures. “Patients should be considered at high risk of coagulopathy if they have reported use or are suspected of using synthetic cannabinoids,” CDC advised.
They point out that confirmation of the case requires the detection of brodifacoum in blood, serum, plasma or urine, as determined by laboratory tests. “Clinicians and health care providers need to work with their health center lab to determine options for the brodifacoum test,” the agency said.
Currently, CDC is coordinating national surveillance activities for potential cases of vitamin K-dependent antagonist coagulopathy linked with the use of synthetic cannabinoids.
Do I have a Synthetic Cannabinoid Lawsuit?
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in synthetic cannabinoid lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.
Free Case Evaluation: Again, if you were harmed by synthetic cannabinoid side effects, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.